Cytek Biosciences Inc., a leading cell analysis solutions company, reported its financial results for the first quarter of 2025. Total revenue for the quarter was $41.5 million, marking a 7.6% decrease compared to the first quarter of 2024. This decline in revenue was attributed to a slowdown in product sales in the US and EMEA regions, although it was partially offset by strong performance in the APAC region and robust service revenue worldwide. The company recorded a gross profit of $20.2 million for the first quarter of 2025, reflecting a 12% decrease from the previous year. Excluding investment income, Cytek reported an Adjusted EBITDA loss of $5.5 million, compared to a loss of $2.6 million in the first quarter of 2024. As of March 31, 2025, Cytek's cash and marketable securities stood at $265.6 million, down from $277.9 million as of December 31, 2024. This decrease of $12.3 million occurred despite a cash expenditure of $10.6 million for the repurchase of Cytek shares during the first quarter. In its 2025 outlook, Cytek revised its full-year revenue guidance to a range between $196 million and $210 million, indicating potential growth of -2% to 5% over the full year 2024, assuming no change in currency exchange rates. Significant operational updates include the expansion to a total installed base of 3,149 Cytek instruments, the commencement of operations in Singapore to enhance manufacturing capacity and global supply flexibility, and the launch of the Cytek Muse® Micro instrument, aimed at simplifying flow cytometry with enhanced precision and versatility.